

# CITATION REPORT

List of articles citing

Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference

DOI: 10.1016/s0149-2918(03)80329-6  
Clinical Therapeutics, 2003, 25, 2724-37.

**Source:** <https://exaly.com/paper-pdf/35517171/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
71	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		
70	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. <i>Der Urologe</i> , <b>2004</b> , 43, 820-8		9
69	Understanding erectile dysfunction medication preference studies. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 367-73	2.8	30
68	Phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>BJU International</i> , <b>2005</b> , 96, 257-80	5.6	153
67	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. <i>BJU International</i> , <b>2005</b> , 96, 1323-32	5.6	78
66	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 680-91	2.9	61
65	Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. <i>Clinical Cornerstone</i> , <b>2005</b> , 7, 57-65		31
64	Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 461-8	1.1	16
63	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 848-55	1.1	30
62	Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. <i>Cancer</i> , <b>2005</b> , 104, 2689-700	6.4	169
61	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. <i>BMC Urology</i> , <b>2005</b> , 5, 18	2.2	43
60	Tadalafil: a clinical update. <i>Aging Health</i> , <b>2005</b> , 1, 203-214		3
59	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 75-84	4	43
58	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , <b>2005</b> , 65, 1621-50	12.1	133
57	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. <i>Drugs</i> , <b>2005</b> , 65, 2245-51	12.1	24
56	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. <i>Actas Urológicas Españolas</i> , <b>2006</b> , 30, 67-79	0.7	7
55	An overview of the diagnosis and treatment of erectile dysfunction. <i>Drugs</i> , <b>2006</b> , 66, 2339-55	12.1	17

54 . 2006,

53 Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. *BJU International*, 2006, 98, 623-9 5.6 22

52 Comparison of phosphodiesterase type 5 (PDE5) inhibitors. *International Journal of Clinical Practice*, 2006, 60, 967-75 2.9 113

51 A 15-item short form of the psychological and interpersonal relationship scales. *International Journal of Impotence Research*, 2006, 18, 82-8 2.3 26

50 Preference studies are of value to the field of sexual medicine: Pro. *Current Sexual Health Reports*, 2006, 3, 6-8 1.2

49 Preference studies are of value to the field of sexual medicine: Con. *Current Sexual Health Reports*, 2006, 3, 9-12 1.2

48 Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. *Journal of Sexual Medicine*, 2006, 3, 901-909 1.1 45

47 Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. *Journal of Sexual Medicine*, 2006, 3, 1037-1049 1.1 44

46 Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. *European Urology*, 2006, 49, 30-7 10.2 43

45 Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. *European Urology*, 2006, 49, 900-7; discussion 907 10.2 16

44 The sexual impact of cancer and cancer treatments in men. *Nursing Clinics of North America*, 2007, 42, 555-80; vi 1.6 19

43 Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. *International Journal of Impotence Research*, 2007, 19, 281-95 2.3 33

42 Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction. *Korean Journal of Urology*, 2007, 48, 219 5

41 Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. *Asian Journal of Andrology*, 2007, 9, 760-70 2.8 16

40 Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). *European Urology*, 2007, 51, 541-50; discussion 550 10.2 44

39 Optimizing response to phosphodiesterase type 5 inhibitors. *Current Sexual Health Reports*, 2007, 4, 1-6 1.2 1

38 Large-scale questionnaire survey of erectile dysfunction drugs in Japanese men. *Reproductive Medicine and Biology*, 2008, 7, 105-114 4.1 1

37 Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. *Journal of Sexual Medicine*, 2008, 5, 1198-1207 1.1 47

36	The impact of formulary replacement of sildenafil by vardenafil at a local VA hospital. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 188-91	2.3	2
35	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , <b>2008</b> , 4, 1315-30	2.9	57
34	Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. <i>Patient Preference and Adherence</i> , <b>2009</b> , 3, 105-11	2.4	9
33	Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. <i>Patient Preference and Adherence</i> , <b>2009</b> , 3, 99-104	2.4	23
32	Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 2836-50	1.1	5
31	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. <i>European Urology</i> , <b>2009</b> , 56, 1067-73	10.2	15
30	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , <b>2009</b> , 48, 1318, 1320-9		7
29	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 629-37	2.8	1
28	Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. <i>BJU International</i> , <b>2009</b> , 103, 1212-7	5.6	39
27	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3486-95	3.3	16
26	Treatment of erectile dysfunction in the older diabetic patient. <i>Aging Health</i> , <b>2010</b> , 6, 9-29		
25	Treatment of Erectile Dysfunction. 341-354		
24	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. <i>International Journal of Impotence Research</i> , <b>2011</b> , 23, 1-8	2.3	17
23	Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 2894-903	1.1	55
22	Medikamentö-induzierte Kopfschmerzen. <i>Aktuelle Neurologie</i> , <b>2012</b> , 39, 351-357		2
21	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1481-94	4	15
20	[Importance of patient's choice in the treatment of erectile dysfunction]. <i>Presse Medicale</i> , <b>2012</b> , 41, 593-7.2		1
19	How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 26-33	1.1	24

18	Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2057-65	1.1	17
17	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , <b>2013</b> , 67, 768-80	2.9	73
16	Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire. <i>International Journal of Urology</i> , <b>2014</b> , 21, 821-5	2.3	8
15	Preference for erectile dysfunction treatments: Assessment by means of consumers preference analysis techniques. <i>Actas Urológicas Españolas (English Edition)</i> , <b>2014</b> , 38, 319-326	0.1	
14	Preference for erectile dysfunction treatments: Assessment by means of consumers preference analysis techniques. <i>Actas Urológicas Españolas</i> , <b>2014</b> , 38, 319-26	0.7	
13	Sexual Function in Men and Women with Diabetes. <b>2016</b> , 716-730		
12	The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 237-47	4.1	39
11	Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , <b>2017</b> , 49, 1731-1740	2.3	43
10	Les traitements oraux de la dysfonction érectile aujourd'hui, pour quel patient?. <i>Sexologies</i> , <b>2018</b> , 27, 37-46	0.5	0
9	Variability in Prices for Erectile Dysfunction Medications-Are All Pharmacies the Same?. <i>Journal of Sexual Medicine</i> , <b>2018</b> , 15, 1785-1791	1.1	6
8	The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. <i>Andrology</i> , <b>2019</b> , 7, 804-817	4.2	10
7	A "real life" investigation on the prescriptive habits among Italian andrologists: The "CONSER" survey from Italian Society of Andrology (SIA) on Sildenafil oral film. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2019</b> , 91,	1.6	4
6	Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	1
5	Sexual Function in Men and Woman with Diabetes. 743-759		1
4	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		1
3	Approaches to the rational choice of type 5 phosphodiesterase inhibitors in patients presenting with cardiovascular and endocrine diseases. <i>Problemy Endokrinologii</i> , <b>2010</b> , 56, 63-72	0	
2	Kopfschmerzen. <b>2006</b> , 3-21		
1	Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. <i>Patient Preference and Adherence</i> , <b>2008</b> , 2, 149-55	2.4	7

